Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: HLA-DRA Class II Molecule as a Marker for Immuno-Active Tumors and Its Role in Predicting Response to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer

  • By

  • Jie Mei

  • Guanyu Jiang

  • Yundi Chen

  • Yongrui Xu

  • Yuan Wan

  • Ruo Chen

  • Feng Liu

  • Wenjun Mao

  • Mingfeng Zheng

  • Junying Xu

  • September 17, 2026

Share

  • 1

    An erratum was issued for BMC Cancer volume 22, article 738 regarding an error in Fig. 5E.

  • 2

    The error involved the duplication of the PR HLA-DRA and PR PD-L1 panels due to incorrect layer arrangement.

  • 3

    A corrected version of Fig. 5E has been provided, showing the appropriate image in the PR PD-L1 panel.

  • 4

    The authors confirm that the correction does not alter the study’s conclusions.

  • 5

    The erratum was published to ensure accuracy in the representation of the study's findings.

Original Source(s)

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

  • by Jie Mei, Guanyu Jiang, Yundi Chen, Yongrui Xu, Yuan Wan, Ruo Chen, Feng Liu, Wenjun Mao, Mingfeng Zheng, Junying Xu

  • September 17, 2026

Related Content

CAR T Before Surgery Improves Glioblastoma Control in Mice

Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

  • September 7, 2026

  • 3 min
Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα

The evolution of RTOG and NRG Oncology CNS tumors clinical trials